Press Releases

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Fluorescent In Situ Hybridization Probe Market size & share revenue was valued at approximately USD 1.14 Billion in 2025 and is expected to reach USD 1.23 Billion in 2026 and is expected to reach around USD 2.27 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Bio-Rad Laboratories Inc., Oxford Gene Technology (Sysmex), Abnova Corporation, Empire Genomics LLC, MetaSystems Group and others.

Miami, FL, June 17, 2026 (GLOBE NEWSWIRE) -- Collective Acquisition Corp. II (Nasdaq: CAIIU) (the “Company”) announced today that, commencing June 22, 2026, holders of the units issued in the Company’s initial public offering (the “Units”), each consisting of one Class A ordinary share of the Company (the “Class A Ordinary Shares”) and one-half of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, may elect to separately trade the Class A Ordinary Shares and Warrants included in the Units. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Class A Ordinary Shares and Warrants will trade on the Nasdaq Global Market under the symbols “CAII” and “CAIIW,” respectively. Units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAIIU.”